199 related articles for article (PubMed ID: 35710397)
1. KAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data.
Zhu S; Bao H; Zhang MC; Liu H; Wang Y; Lin C; Zhao X; Liu SL
BMC Cancer; 2022 Jun; 22(1):662. PubMed ID: 35710397
[TBL] [Abstract][Full Text] [Related]
2. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
Singh A; Gupta S; Badarukhiya JA; Sachan M
Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
[TBL] [Abstract][Full Text] [Related]
3. [Relationships between decreased LAMC3 and poor prognosis in ovarian cancer].
Lei SM; Liu X; Xia LP; Ke Y; Wei LW; Li L; Yin FJ
Zhonghua Fu Chan Ke Za Zhi; 2021 Jul; 56(7):489-497. PubMed ID: 34304441
[No Abstract] [Full Text] [Related]
4. Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer.
Liang L; Zhang Y; Li C; Liao Y; Wang G; Xu J; Li Y; Yuan G; Sun Y; Zhang R; Li X; Nian W; Zhao J; Zhang Y; Zhu X; Wen X; Cai S; Li N; Wu L
EBioMedicine; 2022 Sep; 83():104222. PubMed ID: 35973389
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.
Huang RL; Gu F; Kirma NB; Ruan J; Chen CL; Wang HC; Liao YP; Chang CC; Yu MH; Pilrose JM; Thompson IM; Huang HC; Huang TH; Lai HC; Nephew KP
Epigenetics; 2013 Jun; 8(6):624-34. PubMed ID: 23774800
[TBL] [Abstract][Full Text] [Related]
6. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
Marinelli LM; Kisiel JB; Slettedahl SW; Mahoney DW; Lemens MA; Shridhar V; Taylor WR; Staub JK; Cao X; Foote PH; Burger KN; Berger CK; O'Connell MC; Doering KA; Giakoumopoulos M; Berg H; Volkmann C; Solsrud A; Allawi HT; Kaiser M; Vaccaro AM; Albright Crawford C; Moehlenkamp C; Shea G; Deist MS; Schoolmeester JK; Kerr SE; Sherman ME; Bakkum-Gamez JN
Gynecol Oncol; 2022 Jun; 165(3):568-576. PubMed ID: 35370009
[TBL] [Abstract][Full Text] [Related]
7. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract][Full Text] [Related]
8. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer.
Jiao J; Jiang L; Luo Y
Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
[TBL] [Abstract][Full Text] [Related]
9. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
Kalachand RD; Stordal B; Madden S; Chandler B; Cunningham J; Goode EL; Ruscito I; Braicu EI; Sehouli J; Ignatov A; Yu H; Katsaros D; Mills GB; Lu KH; Carey MS; Timms KM; Kupryjanczyk J; Rzepecka IK; Podgorska A; McAlpine JN; Swisher EM; Bernards SS; O'Riain C; O'Toole S; O'Leary JJ; Bowtell DD; Thomas DM; Prieske K; Joosse SA; Woelber L; Chaudhry P; Häfner N; Runnebaum IB; Hennessy BT
J Natl Cancer Inst; 2020 Dec; 112(12):1190-1203. PubMed ID: 32413141
[TBL] [Abstract][Full Text] [Related]
11. Increased Expression of
Zou R; Xu H; Li F; Wang S; Zhu L
DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic profiling and mRNA expression reveal candidate genes as biomarkers for colorectal cancer.
Zhang H; Dong S; Feng J
J Cell Biochem; 2019 Jun; 120(6):10767-10776. PubMed ID: 30672027
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of Epithelial Splicing Regulatory Protein 1 in Metastatic Lesions of Serous Ovarian Carcinoma Correlates with Poor Patient Prognosis.
Lu X; Li R; Wang X; Guo Q; Wang L; Zhou X
Cancer Biother Radiopharm; 2022 Nov; 37(9):850-861. PubMed ID: 34495766
[No Abstract] [Full Text] [Related]
14. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.
Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB
Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor 2 mRNA-binding protein 2 is a therapeutic target in ovarian cancer.
Yuan J; Li X; Wang F; Liu H; Guan W; Xu G
Exp Biol Med (Maywood); 2023 Dec; 248(23):2198-2209. PubMed ID: 38084732
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
Diao B; Yang P
Pathol Oncol Res; 2021; 27():1609855. PubMed ID: 34512203
[TBL] [Abstract][Full Text] [Related]
17. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer.
Wu Y; Zhang X; Lin L; Ma XP; Ma YC; Liu PS
Asian Pac J Cancer Prev; 2014; 15(3):1171-6. PubMed ID: 24606436
[TBL] [Abstract][Full Text] [Related]
18. Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer.
Sung HY; Yang SD; Park AK; Ju W; Ahn JH
Yonsei Med J; 2017 Jan; 58(1):27-34. PubMed ID: 27873492
[TBL] [Abstract][Full Text] [Related]
19. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
[TBL] [Abstract][Full Text] [Related]
20. Gene Signatures and Prognostic Values of m6A RNA Methylation Regulators in Ovarian Cancer.
Han X; Liu J; Cheng G; Cui S
Cancer Control; 2020; 27(1):1073274820960460. PubMed ID: 32951457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
